Drugs / Anti-CsbD Bovine IgG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00524004 | Jan → Oct 2007 | diarrheal disease | Johns Hopkins Bloomberg School of Public Health | Completed | Mixed |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-CsbD Bovine IgG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00524004 ↗ |
| Modality | Protein / enzyme biologic | “bovine colostral IgG (bIgG) antibodies against a CF, CS17, or antibodies against CsbD” PMID 30897198 ↗ Jul 2019 |
| Route | Oral | “receive oral bIgG against CS17, CsbD, or placebo” PMID 30897198 ↗ Jul 2019 |